進行性核上神經麻痹症市場分析及預測（至2035年）：依類型、產品類型、技術、應用、最終使用者、服務、設備、組件、疾病階段分類

進行性核上神經麻痹症（PSP）市場預計將從2024年的1.223億美元成長到2034年的5.464億美元，複合年成長率約為16.1%。 PSP市場涵蓋了PSP（一種罕見的神經退化性疾病）治療方法的研發、進行性核上神經麻痹症和分銷。該市場專注於創新藥物研發、症狀治療和支持性護理解決方案。人們對PSP的認知不斷提高，診斷技術的進步也推動了對有效PSP管理方案的需求，從而促進了對研發和臨床試驗的投資，旨在滿足未被滿足的需求並提高患者的生活品質。

進行性核上神經麻痹症（PSP）市場預計將迎來顯著成長，這主要得益於治療性介入的進步和公眾意識的提高。治療細分市場是推動市場成長的主要因素，其中藥物療法在症狀管理方面展現出巨大潛力。左旋多巴和多巴胺促效劑預計將繼續保持該細分市場的領先地位，為患者緩解症狀做出貢獻。非藥物療法，包括物理療法和職業療法，透過補充藥物治療並改善患者的生活品質，正逐漸成為第二大細分舉措有望加速創新並拓展治療選擇。人們日益認知到，多學科協作對於PSP的全面管理至關重要。

市場概況：

進行性核上神經麻痹症（PSP）市場的特徵是市場佔有率、定價策略和新產品發布之間存在著動態的相互作用。市場領導正利用創新的定價模式來提高產品的可及性和競爭優勢。近期推出的新產品引進了先進的治療方案，正在重塑治療模式。這些發展加劇了競爭格局，各公司透過策略聯盟和前沿研究舉措來爭奪主導。此外，以患者為中心的解決方案也推動了市場差異化。競爭基準分析凸顯了主要參與者之間的激烈競爭，少數幾家公司憑藉強大的研發能力主導市場。監管的影響至關重要，嚴格的指導方針規範市場准入和產品開發。歐洲和北美市場深受法規結構的影響，這些框架旨在確保產品的安全性和有效性，從而影響競爭策略。新興市場蘊藏著巨大的未開發潛力，預計放鬆管制將推動市場成長。持續創新和遵守不斷變化的法規仍然是保持市場領先地位的關鍵。

主要趨勢和促進因素：

進行性核上神經麻痹症（PSP）市場正經歷著變革性成長，這主要得益於神經退化性疾病研究的進展以及對PSP病理學更深入的理解。一個關鍵趨勢是標靶治療的加速研發，這些療法不僅旨在緩解症狀，更著眼於預防疾病進展。這項轉變的驅動力在於生物標記辨識方面的突破，從而實現了早期診斷和更完善的個人化治療方案。此外，製藥公司與研究機構之間更緊密的合作正在推動創新並加快臨床試驗進程。鑑於對這種罕見疾病有效治療方法的迫切需求，各國政府和醫療機構正在加大對PSP研究的投入。 PSP盛行率的上升以及人口老化進一步刺激了市場需求。此外，患者權益倡導組織在提高公眾意識和資金籌措方面發揮關鍵作用，影響研究重點和政策決策。數位健康技術的進步正推動人們更加重視透過遠端醫療和遠端監測來改善PSP管理中的患者照護和臨床療效。

限制與挑戰：

進行性核上神經麻痹症（PSP）市場面臨許多重大限制與挑戰。其中一個關鍵限制因素是我們對PSP病理生理機制的了解有限，阻礙了標靶治療的研發。這種複雜性增加了研究成本，延長了藥物研發週期，從而抑制了投資。此外，PSP的罕見性意味著患者群體較小，降低了製藥公司投資PSP特異性治療方法的經濟獎勵。醫療專業人員對此疾病的認知不足導致誤診和延遲診斷，對患者預後和市場潛力產生負面影響。治療方案的高成本進一步限制了市場成長，許多患者面臨經濟障礙，難以獲得治療。監管障礙也是一大挑戰，新治療方法嚴格的核准流程可能會延遲其上市。最後，缺乏完善的病患支援體系限制了資訊和資源的傳播，進一步限制了市場擴張。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

• 宏觀經濟分析
• 市場趨勢
• 市場促進因素
• 市場機遇
• 市場限制
• 複合年均成長率：成長分析
• 影響分析
• 新興市場
• 技術藍圖
• 戰略框架

第4章 細分市場分析

• 市場規模及預測：依類型
  • 經典進行性核上神經麻痹症
  • 理查森症候群
  • 進行性核上性麻痺-帕金森氏症
  • 進行性核上性麻痺-皮質基底節症候群
  • PSP－進行性非流利性失語症
  • 進行性核額顳葉型失智症
• 市場規模及預測：依產品分類
  • 製藥
  • 生物製藥
  • 基因治療
  • 診斷試劑盒
  • 神經保護劑
  • 症狀治療
• 市場規模及預測：依技術分類
  • 磁振造影診斷
  • PET掃描
  • 生物標記分析
  • 基因檢測
  • 神經心理學測試
• 市場規模及預測：依應用領域分類
  • 臨床診斷
  • 研究與開發
  • 治療應用
• 市場規模及預測：依最終用戶分類
  • 醫院
  • 診斷檢查室
  • 研究所
  • 學術機構
  • 製藥公司
• 市場規模及預測：依服務分類
  • 醫療諮詢
  • 遺傳諮詢
  • 復健服務
  • 安寧療護
• 市場規模及預測：依設備分類
  • 診斷影像設備
  • 診斷設備
  • 監控設備
• 市場規模及預測：依組件分類
  • 活性成分
  • 添加劑
  • 生物成分
• 市場規模及預測：依發展階段分類
  • 早期
  • 中級階段
  • 晚期

第5章 區域分析

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲地區
• 亞太地區
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲
  • 台灣
  • 亞太其他地區
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 其他歐洲地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 撒哈拉以南非洲
  • 其他中東和非洲地區

第6章 市場策略

• 需求與供給差距分析
• 貿易和物流限制
• 價格、成本和利潤率趨勢
• 市場滲透率
• 消費者分析
• 法規概述

第7章 競爭訊息

• 市場定位
• 市場占有率
• 競爭基準
• 主要企業的策略

第8章 公司簡介

• Asceneuron
• TauRx Pharmaceuticals
• AlzProtect
• Anavex Life Sciences
• ProMIS Neurosciences
• Cortexyme
• Intra-Cellular Therapies
• Denali Therapeutics
• BioVie
• Cassava Sciences
• Alector
• Cognition Therapeutics
• Sangamo Therapeutics
• Voyager Therapeutics
• AC Immune

第9章：關於我們

Progressive Supranuclear Palsy Market is anticipated to expand from $122.3 million in 2024 to $546.4 million by 2034, growing at a CAGR of approximately 16.1%. The Progressive Supranuclear Palsy (PSP) Market encompasses the development, production, and distribution of therapies targeting PSP, a rare neurodegenerative disorder. This market focuses on innovative drug development, symptomatic treatments, and supportive care solutions. With increasing awareness and diagnostic advancements, the demand for effective PSP management is rising, spurring investment in research and clinical trials to address unmet medical needs and improve patient quality of life.

The Progressive Supranuclear Palsy (PSP) Market is poised for substantial growth, driven by advancements in therapeutic interventions and increasing awareness. The treatment segment is leading in performance, with pharmacological therapies showing significant promise in symptom management. Within this segment, levodopa and dopamine agonists are anticipated to remain top-performing sub-segments, offering symptomatic relief to patients. Non-pharmacological therapies, including physical and occupational therapies, are emerging as the second highest performing sub-segments, complementing drug treatments by enhancing patients' quality of life. Diagnosis and monitoring tools are also witnessing notable advancements, with imaging techniques and biomarker identification gaining traction. These tools are critical for early detection and disease progression tracking. Research and development efforts are intensifying, focusing on novel drug formulations and delivery methods. Collaborative initiatives between pharmaceutical companies and research institutions are expected to accelerate innovation and expand therapeutic options. A multidisciplinary approach is increasingly recognized as essential for comprehensive PSP management.

Market Snapshot:

The Progressive Supranuclear Palsy market is characterized by a dynamic interplay of market share, pricing strategies, and new product launches. Market leaders are leveraging innovative pricing models to enhance accessibility and competitive advantage. Recent product launches have introduced advanced therapeutic options, which are reshaping treatment paradigms. These developments are fostering a competitive landscape where companies are vying for prominence through strategic collaborations and cutting-edge research initiatives. Additionally, a focus on patient-centric solutions is driving market differentiation. Competition benchmarking reveals a landscape marked by intense rivalry among key players, with a few companies dominating due to their robust R&D capabilities. Regulatory influences are pivotal, with stringent guidelines shaping market entry and product development. The European and North American markets are heavily influenced by regulatory frameworks that ensure safety and efficacy, impacting competitive strategies. Emerging markets present untapped potential, with regulatory easing anticipated to stimulate growth. Continuous innovation and compliance with evolving regulations remain critical for sustained market leadership.

Geographical Overview:

The Progressive Supranuclear Palsy (PSP) market is witnessing notable developments across various regions, each exhibiting unique growth dynamics. North America remains at the forefront, propelled by advanced healthcare infrastructure and robust research initiatives. The region's focus on neurological research and clinical trials enhances its market position. Europe follows closely, with countries like Germany and the United Kingdom investing heavily in PSP research and treatment options. The region's emphasis on healthcare innovation and patient care contributes significantly to its market growth. In the Asia Pacific, the PSP market is expanding rapidly, driven by increasing awareness and improved healthcare access. Emerging economies such as China and India are investing in neurological research, creating new growth pockets. Latin America and the Middle East & Africa are also emerging markets with growing potential. These regions are recognizing the importance of early diagnosis and treatment in managing PSP, leading to increased healthcare investments and market opportunities.

Key Trends and Drivers:

The Progressive Supranuclear Palsy (PSP) market is experiencing transformative growth, driven by advancements in neurodegenerative disease research and increased understanding of PSP's pathophysiology. One key trend is the accelerated development of targeted therapies, aiming to modify disease progression rather than merely alleviating symptoms. This shift is facilitated by breakthroughs in biomarker identification, enhancing early diagnosis and personalized treatment approaches. Additionally, collaborations between pharmaceutical companies and research institutions are intensifying, fostering innovation and expediting clinical trials. Governments and healthcare organizations are increasing investments in PSP research, recognizing the need for effective treatments for this rare condition. The rising prevalence of PSP, coupled with an aging population, is further propelling market demand. Moreover, patient advocacy groups are playing a crucial role in raising awareness and funding, influencing research priorities and policy decisions. As digital health technologies advance, there is a growing emphasis on utilizing telemedicine and remote monitoring to improve patient care and clinical outcomes in PSP management.

Restraints and Challenges:

The Progressive Supranuclear Palsy (PSP) market encounters several significant restraints and challenges. A primary restraint is the limited understanding of PSP's pathophysiology, which hampers the development of targeted therapies. This complexity increases research costs and prolongs the drug development timeline, discouraging investment. Additionally, the rarity of PSP results in a smaller patient population, which diminishes the financial incentive for pharmaceutical companies to invest in PSP-specific treatments. The lack of awareness among healthcare professionals often leads to misdiagnosis or delayed diagnosis, negatively impacting patient outcomes and market potential. The high cost of treatment options further restricts market growth, as many patients face financial barriers to accessing care. Regulatory hurdles also pose a challenge, as stringent approval processes for new therapies can delay market entry. Finally, the absence of a robust patient support infrastructure limits the dissemination of information and resources, further constraining market expansion.

Key Players:

Asceneuron, TauRx Pharmaceuticals, AlzProtect, Anavex Life Sciences, ProMIS Neurosciences, Cortexyme, Intra-Cellular Therapies, Denali Therapeutics, BioVie, Cassava Sciences, Alector, Cognition Therapeutics, Sangamo Therapeutics, Voyager Therapeutics, AC Immune

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Services
• 2.7 Key Market Highlights by Device
• 2.8 Key Market Highlights by Component
• 2.9 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Classic Progressive Supranuclear Palsy
  • 4.1.2 Richardson's Syndrome
  • 4.1.3 PSP-Parkinsonism
  • 4.1.4 PSP-Corticobasal Syndrome
  • 4.1.5 PSP-Progressive Nonfluent Aphasia
  • 4.1.6 PSP-Frontotemporal Dementia
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Pharmaceuticals
  • 4.2.2 Biologics
  • 4.2.3 Gene Therapy
  • 4.2.4 Diagnostic Kits
  • 4.2.5 Neuroprotective Agents
  • 4.2.6 Symptomatic Treatments
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 MRI Imaging
  • 4.3.2 PET Scans
  • 4.3.3 Biomarker Analysis
  • 4.3.4 Genetic Testing
  • 4.3.5 Neuropsychological Testing
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Clinical Diagnostics
  • 4.4.2 Research and Development
  • 4.4.3 Therapeutic Applications
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals
  • 4.5.2 Diagnostic Laboratories
  • 4.5.3 Research Institutes
  • 4.5.4 Academic Institutions
  • 4.5.5 Pharmaceutical Companies
• 4.6 Market Size & Forecast by Services (2020-2035)
  • 4.6.1 Medical Consultation
  • 4.6.2 Genetic Counseling
  • 4.6.3 Rehabilitation Services
  • 4.6.4 Palliative Care
• 4.7 Market Size & Forecast by Device (2020-2035)
  • 4.7.1 Imaging Devices
  • 4.7.2 Diagnostic Devices
  • 4.7.3 Monitoring Devices
• 4.8 Market Size & Forecast by Component (2020-2035)
  • 4.8.1 Active Pharmaceutical Ingredients
  • 4.8.2 Excipients
  • 4.8.3 Biological Components
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Early Stage
  • 4.9.2 Intermediate Stage
  • 4.9.3 Advanced Stage

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Services
    • 5.2.1.7 Device
    • 5.2.1.8 Component
    • 5.2.1.9 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Services
    • 5.2.2.7 Device
    • 5.2.2.8 Component
    • 5.2.2.9 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Services
    • 5.2.3.7 Device
    • 5.2.3.8 Component
    • 5.2.3.9 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Services
    • 5.3.1.7 Device
    • 5.3.1.8 Component
    • 5.3.1.9 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Services
    • 5.3.2.7 Device
    • 5.3.2.8 Component
    • 5.3.2.9 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Services
    • 5.3.3.7 Device
    • 5.3.3.8 Component
    • 5.3.3.9 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Services
    • 5.4.1.7 Device
    • 5.4.1.8 Component
    • 5.4.1.9 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Services
    • 5.4.2.7 Device
    • 5.4.2.8 Component
    • 5.4.2.9 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Services
    • 5.4.3.7 Device
    • 5.4.3.8 Component
    • 5.4.3.9 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Services
    • 5.4.4.7 Device
    • 5.4.4.8 Component
    • 5.4.4.9 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Services
    • 5.4.5.7 Device
    • 5.4.5.8 Component
    • 5.4.5.9 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Services
    • 5.4.6.7 Device
    • 5.4.6.8 Component
    • 5.4.6.9 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Services
    • 5.4.7.7 Device
    • 5.4.7.8 Component
    • 5.4.7.9 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Services
    • 5.5.1.7 Device
    • 5.5.1.8 Component
    • 5.5.1.9 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Services
    • 5.5.2.7 Device
    • 5.5.2.8 Component
    • 5.5.2.9 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Services
    • 5.5.3.7 Device
    • 5.5.3.8 Component
    • 5.5.3.9 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Services
    • 5.5.4.7 Device
    • 5.5.4.8 Component
    • 5.5.4.9 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Services
    • 5.5.5.7 Device
    • 5.5.5.8 Component
    • 5.5.5.9 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Services
    • 5.5.6.7 Device
    • 5.5.6.8 Component
    • 5.5.6.9 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Services
    • 5.6.1.7 Device
    • 5.6.1.8 Component
    • 5.6.1.9 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Services
    • 5.6.2.7 Device
    • 5.6.2.8 Component
    • 5.6.2.9 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Services
    • 5.6.3.7 Device
    • 5.6.3.8 Component
    • 5.6.3.9 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Services
    • 5.6.4.7 Device
    • 5.6.4.8 Component
    • 5.6.4.9 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Services
    • 5.6.5.7 Device
    • 5.6.5.8 Component
    • 5.6.5.9 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Asceneuron
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 TauRx Pharmaceuticals
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 AlzProtect
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Anavex Life Sciences
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 ProMIS Neurosciences
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Cortexyme
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Intra-Cellular Therapies
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Denali Therapeutics
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 BioVie
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Cassava Sciences
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Alector
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Cognition Therapeutics
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Sangamo Therapeutics
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Voyager Therapeutics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 AC Immune
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us